|
Solvent |
mg/mL |
mM |
| Solubility |
| Soluble in DMSO |
0.0 |
100.00 |
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.
Preparing Stock Solutions
The following data is based on the
product
molecular weight
414.59
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Sieber-Ruckstuhl NS, Reusch CE, Hofer-Inteeworn N, Kuemmerle-Fraune C, Müller C, Hofmann-Lehmann R, Boretti FS. Evaluation of a low-dose desoxycorticosterone pivalate treatment protocol for long-term management of dogs with primary hypoadrenocorticism. J Vet Intern Med. 2019 May;33(3):1266-1271. doi: 10.1111/jvim.15475. Epub 2019 Mar 13. PMID: 30865322; PMCID: PMC6524388.
2: Lathan P, Thompson AL. Management of hypoadrenocorticism (Addison's disease) in dogs. Vet Med (Auckl). 2018 Feb 9;9:1-10. doi: 10.2147/VMRR.S125617. PMID: 30050862; PMCID: PMC6055912.
3: Deng Y, Xie M, Li Q, Xu X, Ou W, Zhang Y, Xiao H, Yu H, Zheng Y, Liang Y, Jiang C, Chen G, Du D, Zheng W, Wang S, Gong M, Chen Y, Tian R, Li T. Targeting Mitochondria-Inflammation Circuit by β-Hydroxybutyrate Mitigates HFpEF. Circ Res. 2021 Jan 22;128(2):232-245. doi: 10.1161/CIRCRESAHA.120.317933. Epub 2020 Nov 12. PMID: 33176578.
4: Jaffey JA, Nurre P, Cannon AB, DeClue AE. Desoxycorticosterone Pivalate Duration of Action and Individualized Dosing Intervals in Dogs with Primary Hypoadrenocorticism. J Vet Intern Med. 2017 Nov;31(6):1649-1657. doi: 10.1111/jvim.14828. Epub 2017 Sep 11. PMID: 28892205; PMCID: PMC5697171.
5: Münch L, Münch M, Paul H, Miklis A, Heinrich M, Neiger R. Therapie des primären Hypoadrenokortizismus beim Hund mit niedrig dosiertem Desoxycorticosteronpivalat [Therapy of primary hypoadrenocorticism in dogs with low dose desoxycorticosterone pivalate]. Tierarztl Prax Ausg K Kleintiere Heimtiere. 2020 Jun;48(3):171-175. German. doi: 10.1055/a-1166-8800. Epub 2020 Jun 18. PMID: 32557492.
6: Solocinski K, Holzworth M, Wen X, Cheng KY, Lynch IJ, Cain BD, Wingo CS, Gumz ML. Desoxycorticosterone pivalate-salt treatment leads to non-dipping hypertension in Per1 knockout mice. Acta Physiol (Oxf). 2017 May;220(1):72-82. doi: 10.1111/apha.12804. Epub 2016 Oct 3. PMID: 27636900; PMCID: PMC5354999.
7: Oblak ML, Bacon NJ, Covey JL. Perioperative Management and Outcome of Bilateral Adrenalectomy in 9 Dogs. Vet Surg. 2016 Aug;45(6):790-7. doi: 10.1111/vsu.12514. Epub 2016 Jul 11. PMID: 27398811.
8: Bates JA, Shott S, Schall WD. Lower initial dose desoxycorticosterone pivalate for treatment of canine primary hypoadrenocorticism. Aust Vet J. 2013 Mar;91(3):77-82; discussion 81-2. doi: 10.1111/avj.12019. PMID: 23438457.
9: McCabe MD, Feldman EC, Lynn RC, Kass PH. Subcutaneous administration of desoxycorticosterone pivalate for the treatment of canine hypoadrenocorticism. J Am Anim Hosp Assoc. 1995 Mar-Apr;31(2):151-5. doi: 10.5326/15473317-31-2-151. PMID: 7773761.
10: Van Zyl M, Hyman WB. Desoxycorticosterone pivalate in the management of canine primary hypoadrenocorticism. J S Afr Vet Assoc. 1994 Sep;65(3):125-9. PMID: 7595920.
